8-K current report · filed Aug 12, 2026

Spero Therapeutics Inc (SPRO) 8-K Current Report: August 12, 2026

Item EX-99.1Item 2.02SPRO overview

Short answer

Spero Therapeutics Inc (SPRO) filed an 8-K current report with the SEC on August 12, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results for quarter ended June 30, 2026 announced by Spero Therapeutics.

Spero Therapeutics Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026 announced by Spero Therapeutics
  • Press release furnished as Exhibit 99.1, the source for financial results and management commentary

Item EX-99.1 · Exhibit EX-99.1

  • Q2 2026 net loss $9.6M, or $0.16 per share, versus $1.7M, or $0.03, in Q2 2025
  • FDA approval of Utebzi, the first oral carbapenem for eligible adult cUTI patients, with GSK commercialization expected by end-2026
  • $105M non-dilutive royalty financing extends projected cash runway into the second half of 2029, while retaining 35% of residual GSK proceeds
  • Exclusive worldwide license for Phase 2-ready SP001, excluding Greater China, shifts strategy toward immunology and IgG4-related disease
  • June 30 cash $50.8M, before July royalty-financing proceeds, supporting SP001 advancement without near-term equity dilution

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Spero Therapeutics Inc 8-K filings

Get the next SPRO 8-K as it lands

Follow SPRO for push alerts, or ask the research agent what this filing means.